Oslo, Norway, April 28, 2021 - the Board of Directors of Vaccibody AS, a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of vaccines and novel immunotherapies, hereby calls for the Annual
General Meeting at meeting room Toppsenteret - FAROS - Building H, Plan 5 in
Gaustadalléen 21, Oslo, Norway at 10:00 CET on May 5, 2021. All documents
regarding the Annual General Meeting are available at the Company's website:
https://www.vaccibody.com/annual-general-meeting/

As a consequence of the extraordinary situation related to the corona virus, the
Board encourages shareholders not to attend the general meeting in person, but
rather to make use of the ability to vote by proxy. The proxy form will be found
at the above weblink.

For further information, please see the Company's website or contact Chairperson
Anders Tuv. Please see below for contact details.

About Vaccibody
Vaccibody AS, is a clinical-stage biopharmaceutical company, dedicated to the
discovery and development of vaccines and novel immunotherapies. The Company
develops vaccines for the treatment cancer and infectious diseases. Vaccibody's
vaccine technology specifically targets antigens to Antigen Presenting Cells,
which are essential for inducing rapid, strong and long-lasting antigen-specific
immune responses and elicit efficacious clinical responses. Its lead product
candidates include VB10.NEO, a cancer neoantigen vaccine, which is exclusively
outlicensed to Genentech and is in phase I/IIa clinical trial for the treatment
of melanoma, lung- , head and neck, renal-, and bladder cancer